Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib Mini-Tablet Formulation and Particle Size Study
NCT03961100Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of entrectinib in solid tumor (2 cohorts), sponsored by Genentech. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity, Area Under the Concentration-Time Curve From Time 0 to Infinity for Metabolite M5 and 2 more. Started Jun 2019; status: completed.
02
Drugs
entrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03961100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961100.